EUVIMEDEUVIMED entdecken
Crossref

Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance

Chun-Hao Lin, Chun-Kuang Tsai, Te-Lin Hsu, Chiu-Mei Yeh, Jyh-Pyng Gau, Chia-Jen Liu

Clinical Lymphoma Myeloma and Leukemia · 2026-07 · 26 (7) · e926-e934

DOI: 10.1016/j.clml.2026.04.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-07. Verfasst von Chun-Hao Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Thrombocytosis. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Taipei Veterans General Hospital, National Science and Technology Council, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Essential thrombocythemia, prefibrotic primary myelofibrosis (pre-PMF), and overt primary myelofibrosis are myeloproliferative neoplasms with overlapping clinical features but different prognoses. We investigated the prognostic impact of thrombocytosis in pre-PMF. METHODS This retrospective study analyzed patients diagnosed with myeloproliferative neoplasms at Taipei Veterans General Hospital from 2002 to 2023. Diagnoses were assigned by integrated clinicopathologic review using World Health Organization criteria. Overall survival was analyzed using Cox proportional hazards models. For complication endpoint, including leukemic transformation, thrombosis, and bleeding, competing-risk methods were used, with death treated as a competing event. RESULTS Among 350 patients with myeloproliferative neoplasms, the median age was 68 years, and 60.3% were male. Compared with pre-PMF patients without thrombocytosis, essential thrombocythemia did not have a significantly different risk of death (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.30-1.97; P = .586), whereas overt primary myelofibrosis had a significantly higher risk of death (HR 2.80, 95% CI 1.10-7.10; P = .030). In pre-PMF, thrombocytosis had a higher risk of death (HR 4.33, 95% CI 1.03-18.12; P = .045). Prognostic factors for worse survival in pre-PMF included constitutional symptoms (adjusted HR 10.81, 95% CI 2.63-44.36, P = .001), leukocytosis (adjusted HR 7.69, 95% CI 1.94-30.54, P = .004), and thrombocytosis (adjusted HR 7.80, 95% CI 1.49-40.82, P = .015). CONCLUSIONS Thrombocytosis was associated with inferior overall survival in pre-PMF. These findings support platelet count as a pragmatic risk stratifier in pre-PMF and highlight the clinical relevance of distinguishing pre-PMF from essential thrombocythemia and overt primary myelofibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisThrombocytosisHumansMaleFemalePrognosisAgedRetrospective StudiesMiddle AgedPhenotypeRisk AssessmentAged, 80 and over

Stichwörter der Autor:innen

Essential thrombocythemiaMyeloproliferative neoplasmsOverall survival

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Medicine, Kinmen Hospital, Mi…
  • Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Emergency and Critical Care Medicine, College of Medicine, National Yang Ming Chiao Tung Universit…

Förderung

  • Taipei Veterans General Hospital
  • National Science and Technology Council
  • Ministry of Science and Technology, Taiwan
  • Melissa Lee Cancer Foundation
  • Taiwan Clinical Oncology Research Foundation
  • Yen Tjing Ling Medical Foundation

Zitieren

APA

Lin, C. H., Tsai, C. K., Hsu, T. L., Yeh, C. M., Gau, J. P., & Liu, C. J. (2026). Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance. Clinical Lymphoma Myeloma and Leukemia, 26(7), e926-e934. https://doi.org/10.1016/j.clml.2026.04.020

Vancouver

Lin CH, Tsai CK, Hsu TL, Yeh CM, Gau JP, Liu CJ. Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance. Clinical Lymphoma Myeloma and Leukemia. 2026;26(7):e926-e934. doi:10.1016/j.clml.2026.04.020

BibTeX
@article{Lin2026,
  author = {Lin, Chun-Hao and Tsai, Chun-Kuang and Hsu, Te-Lin and Yeh, Chiu-Mei and Gau, Jyh-Pyng and Liu, Chia-Jen},
  title = {Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {e926--e934},
  doi = {10.1016/j.clml.2026.04.020}
}
Kostenlos starten →